Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News

Child standing on scale | Image Credit: Protsenko Dmitriy - stock.adobe.com
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients

January 13th 2025

Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.

Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

June 18th 2024

FDA Approved - chrisdorney - stock.adobe.com.jpg
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

March 7th 2024

Red Blood Cells - Design Cells stock.adobe.com
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

December 22nd 2023

Highlights from ASH 2023
ICYMI: Highlights From ASH 2023

December 20th 2023

Continuing Medical Education
View All
January 16th 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
January 16th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
January 16th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

Doctor comforting patient
September 23rd 2021

Better Knowledge Needed of Unmet Needs of Cancer Survivors

Laura Joszt, MA
Two posters presented at the European Society of Medical Oncology highlighted the unmet needs of cancer survivors.
BTK Inhibition in CLL: Successes and Challenges
September 19th 2021

BTK Inhibition in CLL: Successes and Challenges

Rose McNulty
A review of current data identified areas of progress in Bruton tyrosine kinase (BTK) inhibition for patients with chronic lymphocytic leukemia (CLL).
Brukinsa
September 15th 2021

Zanubrutinib Gains Accelerated Approval in R/R Marginal Zone Lymphoma

Mary Caffrey
This is the third approval for zanubrutinib, which is sold as Brukinsa by BeiGene.
group of young adults
September 14th 2021

Posters Highlight Need for Psychosocial Support in Adolescent Survivors of Childhood Leukemia

Laura Joszt, MA
Two posters being presented at the European Society for Medical Oncology Congress 2021 highlighted the need to provide long-term psychosocial support for adolescents who survive childhood leukemia.
Tubes with blood stem cells
September 10th 2021

Researchers Find Insight Into Risk of Developing AML

Jaime Rosenberg
In a recent study, researchers were able to show how different evolutionary forces in aging blood stem cells impact whether or not someone develops acute myeloid leukemia (AML), offering insight into those at higher risk of the disease.
pill graphic
September 9th 2021

Data Support Once-Daily Dosing of Zanubrutinib for MCL

Gianna Melillo
Results of a data analysis found once-daily zanubrutinib dosing in patients with mantle cell lymphoma (MCL) is safe and effective.
researchers in a laboratory
September 6th 2021

Ongoing Research Aims to Elucidate Underlying Drivers of HCL

Jaime Rosenberg
Unlike most other cancers, the progression of hairy cell leukemia is largely driven by extended cell survival rather than increased proliferative cell fractions.
Graphic of blood cells
September 6th 2021

Study Examines Treatment Link to Transplant Complication in GVHD

Jaime Rosenberg
Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.
FDA
September 2nd 2021

FDA Approves Zanubrutinib in Adults With Waldenström Macroglobulinemia

Laura Joszt, MA
The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma.
Chronic lymphocytic leukemia image
September 1st 2021

Researchers Identify Potential Approach to Overcoming CLL CAR T-Cell Resistance

Jaime Rosenberg
The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.
health graphic
August 29th 2021

HSC Transplantation, Killer-Cell Combo May Lower Risk of GVHD in Leukemia

Jaime Rosenberg
The meta-analysis collected findings from 11 studies, from which researchers determined statistical heterogeneity regarding the incidence of GVHD between patients receiving only HSC transplantation or only killer cell therapy, and patients receiving HSC transplantation in addition to killer cell therapy.
bunch of older men sitting next to each other with 1 black man looking at the camera
August 26th 2021

Study Reveals Poor Prognostic Factors Associated With DLBCL of the Urinary Tract

Skylar Jeremias
A recent study found that older age, male gender, lack of surgical resection or chemotherapy, and late-stage disease may be poor prognostic factors for diffuse large B-cell lymphoma (DLBCL) of the urinary tract.
Study analysis
August 23rd 2021

AML Treatment Improves Complete Remission, Total Effectiveness Rates

Jaime Rosenberg
The researchers of a new analysis argue that the treatments they investigated for acute myelogenous leukemia (AML) are worthy of clinical promotion based on their findings, which they say also provide evidence-based guidance for clinical practice.
DNA strand
August 22nd 2021

Patients With AML May Acquire TP53 Mutations Over the Course of Therapy

Laura Joszt, MA
Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial.
Health Insurance, Blood Cancer Care, and Outcomes: A Literature Review
August 17th 2021

Health Insurance, Blood Cancer Care, and Outcomes: A Literature Review

Karen Crotty, PhD, MPH Marialanna Lee, MSC Katherine Treiman, PhD Maria Sae-Hau, PhD Candi Wines, MPH Catherine Viator, MS Elisa Weiss, PhD
doi: 10.37765/ajmc.2021.88733
Conference Coverage: European Hematology Association 2021 Virtual Congress
August 17th 2021

Conference Coverage: European Hematology Association 2021 Virtual Congress

Laura Joszt, MA Maggie L. Shaw Anthony Hagen Mary Caffrey
researchers in a laboratory
August 16th 2021

Breast Cancer Drug May Also Treat Myelofibrosis, Reduce Bone Marrow Scarring

AJMC Staff
The breast cancer drug palbociclib may be able to treat myelofibrosis either alone or in combination with ruxolitinib.
pediatric care
August 10th 2021

Pediatric ALL Relapse May Be Caused by Mutations From Chemotherapy

Laura Joszt, MA
Chemotherapy is standard care for pediatric acute lymphoblastic leukemia (ALL), but new research shows thiopurines can cause mutations that result in relapse.
Disparities Persist in the Long Term for 5-Year AYA Survivors of Hodgkin Lymphoma
August 4th 2021

Disparities Persist in the Long Term for 5-Year AYA Survivors of Hodgkin Lymphoma

Laura Joszt, MA
Treatment-related modifications have resulted in improved long-term outcomes for all adolescent and young adult (AYA) survivors of Hodgkin lymphoma, but new research highlights that racial, ethnic, and socioeconomic status disparities persist in the long term.
Positive Results From SEQUOIA Analyses for Zanubrutinib in Treatment-Naive CLL and SLL
July 31st 2021

Positive Results From SEQUOIA Analyses for Zanubrutinib in Treatment-Naive CLL and SLL

AJMC Staff
In an interim analyses of the phase 3 SEQUOIA trial, zanubrutinib had superior progression-free survival compared with bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
Patient in mask with doctor on telehealth
July 30th 2021

Understanding the Management of CLL in the Time of COVID-19

Jaime Rosenberg
In a recent review article, a researcher outlined current guidance for the management of patients with chronic lymphocytic leukemia (CLL) as the pandemic continues throughout the country.
Real-world Data Show Higher Incidence of Neutropenia With Venetoclax, Obinutuzumab Combo in CLL
July 22nd 2021

Real-world Data Show Higher Incidence of Neutropenia With Venetoclax, Obinutuzumab Combo in CLL

Jaime Rosenberg
Across 19 patients, 73% developed grade 3 or 4 neutropenia, significantly higher than the incidence observed in the phase 3 trial examining the combination for chronic lymphocytic leukemia (CLL).
cancer patient
July 16th 2021

Therapy Can Prevent Infections in Immunocompromised Patients With Leukemia

Laura Joszt, MA
A new treatment using human immune cells can prevent infections in patients with leukemia who have a weakened immune system due to treatment for their disease.
AML
July 13th 2021

MRD-Guided Decisions May Aid Postremission Treatment Choices in Type of AML

Jaime Rosenberg
Based on subgroup analyses of over 500 younger patients with intermediate-risk disease, the researchers say measurable residual disease (MRD)-guided decisions may help achieve better outcomes postremission.
Genomic Landscapes and Outcomes in Elderly Patients With AML
July 9th 2021

Genomic Landscapes and Outcomes in Elderly Patients With AML

Laura Joszt, MA
Posters presented at the European Hematology Association 2021 Virtual Congress evaluated acute myeloid leukemia (AML) in elderly patients.
Treatment of acute lymphoblastic leukemia
July 5th 2021

Researchers Offer Road Map for CAR T-Cell Treatment for B-ALL

Jaime Rosenberg
The researchers outlined patient selection for treatment, adverse event management, and future strategies for the treatment of these patients.
patient with cancer
July 4th 2021

Real-world Data Show Patterns of Care Don’t Follow Recommendations in Mantle Cell Lymphoma

Laura Joszt, MA
A retrospective analysis of real-world data found a discrepancy between actual care and the recommendations from clinical trials for patients with mantle cell lymphoma, resulting in outcomes that were worse than in trials.
Studies Offer Promising Data on CAR T-Cell Therapy in B-ALL, Multiple Myeloma
July 2nd 2021

Studies Offer Promising Data on CAR T-Cell Therapy in B-ALL, Multiple Myeloma

Jaime Rosenberg
Two abstracts presented recently at the American Society of Clinical Oncology annual meeting offered promising data for 2 CAR T-cell therapies, one in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and one in R/R multiple myeloma.
NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia
June 28th 2021

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

Laura Joszt, MA
The National Comprehensive Cancer Network (NCCN) has updated its guidelines for Waldenström macroglobulinemia to include zanubrutinib (Brukinsa) as a preferred regimen.
social media
June 26th 2021

Using Social Media for Insight Into Patient Experience With ALL and Its Treatments

Laura Joszt, MA
An analysis of social media posts provides insight into patient experiences of acute lymphoblastic leukemia (ALL) and the therapies that treat it.
<1
...
34567891011
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo